PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Highlight RSV Program Data at Two Upcoming Meetings

GAITHERSBURG, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.

Oral presentation details are as follows: 

IDWeek 2018 Meeting
     
Title:   Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants
Presenter:   Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc.
Session:   213. Late Breaker Oral Abstracts: Influenza and Vaccines 
Date and Time:   Saturday, October 6, 11:20 a.m. P.T.
Location:   Moscone Convention Center S 152-154
     
11th International Respiratory Syncytial Virus Symposium
     
Title:   Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F Nanoparticle Vaccine Adjuvanted with Aluminum Phosphate, or a Novel Adjuvant
Presenter:    Vivek Shinde, M.D., M.P.H., Executive Director, Clinical Development, Novavax, Inc.
Session:   5. Advancements in RSV Vaccines
Date and Time:   Thursday, November 1, 4:45 p.m. – 6:15 p.m. E.T.
Location:   Omni Grove Park Inn
     
Title:    Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants
Presenter:   Louis F. Fries III, M.D., Senior Vice President and Chief Medical Officer, Novavax, Inc.
Session:    12. Maternal Immunity & Maternal Vaccination
Date:   Saturday, November 3, 3:00 p.m. – 4:30 p.m. E.T.
Location:    Omni Grove Park Inn
     

Poster presentations for the 11th International Respiratory Syncytial Virus Symposium will occur on Thursday, November 1, 11:30 a.m.12:30 p.m. E.T. and on Friday, November 2, 8:30 p.m.10:00 p.m. E.T. at the Omni Grove Park Inn.

Title:   Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization
Presenter:   Yen-Huei Lin, Ph.D., Senior Director, Formulation and Drug Product Development, Novavax, Inc.
     
Title:   Binding Kinetics of RSVF Prefusogenic Vaccine to Palivizumab and Serum Polyclonal Antibody
Presenter:    Hanxin Lu, Ph.D., Principal Scientist, Novavax, Inc.
     
Title:   In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine
Presenter:   Ernest Maynard, Ph.D., Principal Scientist, Analystical Development, Novavax, Inc.
     
Title:   Antigenic Characterization Prefusogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats
Presenter:   Nita Patel, Director, Antibody Discovery, Vaccine Development Novavax, Inc.
     
Title:   Respiratory Syncytial Virus (RSV) Prefusogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection
Presenter:   Gale Smith, Ph.D., Vice President, Vaccine Development, Novavax, Inc.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:      

Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502

Novavax logo

Source: Novavax, Inc.